1 The present study attempted to determine whether noradrenaline (NA) NA release were investigated. 3 In rabbit hippocampus, 5-HT, 5-carboxamidotryptamine (5-CT; 32 pM) and 2-CH3-5-HT (32 pM) increased [3H]-NA release elicited with 360 pulses/3 Hz. Facilitation of transmitter release was not influenced by the 5-HT3 receptor antagonist, tropisetron but was prevented by the a2-adrenoceptor antagonist, rauwolscine. When autoinhibition was avoided by stimulating the tissue with 4 pulses/100 Hz (pseudo-one pulse-(POP) stimulation), 2-CH3-5-HT decreased evoked transmitter release, whereas 5-HT and 5-CT had no effect. Inhibition caused by 2-CH3-5-HT was not affected by tropisetron but counteracted by the x2-adrenoceptor ligands, clonidine and rauwolscine. Inhibition caused by clonidine was diminished in the presence of 5-CT or 2-CH3-5-HT.
Introduction
The existence of regulatory 5-hydroxytryptamine (5-Hr) receptors located on postganglionic sympathetic nerve terminals has been demonstrated for various tissues of different species. In rat vena cava (Molderings et al., 1987) and human saphenous vein ) depolarization-induced noradrenaline (NA) release is inhibited by activation of 5-HTIB and 5-HTD receptors, respectively. In pig coronary artery (Molderings et al., 1989 ) the inhibitory presynaptic 5-HT receptor seems to belong to the 5-HT4 receptor class. In contrast, for the central nervous system, it is not clear whether 5-HT receptors modulate NA release. For example, electricallyevoked [jH]-NA release from slices of rat neocortex was not affected by 5-HT and 5-HT receptor ligands (Taube et al., 1977) , whereas in rabbit hippocampus 5-HT, blockers of 5-HT re-uptake, the 5-HT1 receptor agonist 5-CT (Pedigo et al., 1981) , and the 5-HT3 receptor agonist, 2-CH3-5-HT (Richardson & Engel, 1986) caused an increase in transmitter release (Feuerstein & Hertfing, 1986) . Moreover, Blandina et al. (1991) demonstrated that K+-evoked release of endogenous NA in rat hypothalamic slices was inhibited by activation of 5-HT3 receptors. The reasons for these discrepancies are unknown. They might result from (i) the use of non-selective receptor ligands affecting more than one presynaptic receptor (ii) differences in the biophase concentration of NA so that a given partial agonist at a2-adrenoceptors could either facilitate or inhibit release, or (iii) a functional interaction between various presynaptic receptors (e.g. Limberger et al, 1988; Allgaier et al., 1989;  1991a; Molderings & Gbthert, 1990 ).
The present investigation continues the previous work of who investigated whether noradrenergic nerve terminals of rabbit hippocampus are equipped with 5-HT receptors modulating depolarization-induced noradrenaline release. To this end, slices derived from either rabbit hippocampus or human neocortex were labelled with [3H]-NA and the effects of 5-HT receptor ligands on electrically-evoked
[3H]-NA release were measured by choosing experimental conditions in which autoinhibition by released NA was avoided.
Preliminary accounts of the present results were given at the Joint Meeting of the Deutsche Gesellschaft fur Pharmakologie und Toxikologie and the Association Francaise des Pharmacologistes (Lille, France, 1993 Bridsh Joumal of Phamacology (1995) 116, 1769 -1774 composition in mM: NaCl 118, KC1 4.8, CaCI2 1.3, MgSO4 1.2, NaHCO3 25, KH2PO4 1.2, glucose 10, ascorbic acid 0.57, Na2 EDTA 0.03; saturated with 5% CO2 in 02, pH 7.4) containing a final concentration of 0.1 gM [3H]-NA (42.1 Ci mmol-1).
Following 3H-labelling (30 min), slices were rinsed and transferred to 12 superfusion chambers (each containing one slice) where they were situated between two platinum plate electrodes. Superfusion (at a flow rate of 0.6 ml min-) was followed with KRBB containing 1 gM (+ )-oxaprotiline, an inhibitor of noradrenaline re-uptake (Waldmeier et al., 1982) . A 'conditioning' stimulation with 18 rectangular pulses of 2 ms duration of 1 Hz was routinely applied 20 min after the beginning of superfusion, since this yielded more reproducible responses to subsequent stimulations. For the 'conditioning' and all subsequent stimulations, voltage drop and current strength were 15 V cm-' and 60 mA (~1.2 mA mm-2 electrode area). Fractions (4 min) of the superfusate were collected, starting after 40 min of superfusion. Electrical field stimulation was carried out after 48 min (SI) and 80 min (S2) with 360 pulses/3 Hz or 4 pulses/100 Hz (POP stimulation). Drugs were added 8 or 16 min before S2. a2-Adrenoceptor ligands were present throughout superfusion as indicated. Superfusion was terminated after 96 min. SI served as the reference stimulus.
In some experiments on human neocortex slices, the usual POP stimulation was replaced by a modified POP stimulation consisting of two bursts of 4 pulses/100 Hz, 3.5 min apart in order to enhance the amount of the evoked tritium overflow. It was established in separate control experiments that with this modified POP stimulation, autoinhibition did not occur (i.e. yohimbine had no facilitatory effect on the evoked overflow; see Results).
Fractional rate of outflow of tritiated compounds per 4 min was determined by expressing the radioactivity in a 4 min-superfusate-fraction as a percentage of the radioactivity in the slice at the beginning of the respective fraction. Stimulation-evoked overflow of tritium from brain slices, which reflects exocytotic release of [3H]-NA (Allgaier et al., 1991a) , was calculated as the difference between the total radioactivity in the 12 min superfusion period after the start of stimulation and the basal radioactivity in that period (basal outflow of tritium was assumed to decline linearly). The difference was expressed as a percentage of the radioactivity in the slice at the beginning of the respective stimulation period (SI%, S2%). Evaluation of drug effects on evoked tritium overflow was performed by calculating the ratio between the overflow evoked by S2 and the overflow evoked by SI (S2/SI). Drug effects on resting outflow of tritium were calculated from the ratio between the fractional rates of tritium outflow in the fraction preceding S2 (b2) and the fraction before SI (bl) . S2/SI and b2/b1 ratios were expressed as a percentage of the corresponding mean S2/S1 and b2/b1 ratios of appropriate controls.
Statistics
All data are given as arithmetic means ± s.e.mean. After Kruskal-Wallis analysis, the significance of differences between the means of various groups was determined by the MannWhitney test. (Table 1) . Transmitter release was significantly facilitated by 5-HT, 5-CT and by 2-CH3-5-HT, each used at 32 gM ( Figure 1 ). The 5-HT3 receptor antagonist, tropisetron (10 gM) had no effect on the agonistinduced facilitation of release which was, however, prevented in the presence of the a2-adrenoceptor antagonist, rauwolscine (Table 1) presumably by counteracting autoinhibition mediated by activation of a2-adrenoceptors.
None of the compounds had an effect on resting tritium outflow (data not shown) except 5-HT (b2/b1 = 133.3 ± 2.0% of control for 32 ,uM 5-HT, n = 5; P<0.01 vs. control). (Table 1) . 5-HT (10 or 32 gM) and 5-CT (1, 10, or 32 gM) had no effect on evoked transmitter release (data not shown). The inhibitory effect of 2-CH3-5-HT was not changed by tropisetron (10 nM) but was abolished by rauwolscine (0.03 or 1 EM) (Figure 2 ). In accordance with previous results (Allgaier et al., 1991b; 1992) rauwolscine had no effect on [3H]-NA release evoked with 4 pulses/100 Hz (Table 1) . Also the a2-adrenoceptor agonist, clonidine (3 nM), which diminished [3H]-NA release by approximately 40% when given alone (Table 1) , counteracted the inhibition caused by 2-CH3-5-HT (Table 2) when it was present throughout the superfusion.
When 5-CT or 2-CH3-5-HT was present throughout superfusion and clonidine (10 nM) was added before S2, the inhibitory effect of clonidine was significantly diminished (Table  3) . SI control ratios were 1.11 (no rauwolscine), 1.16 (with 0.03pM rauwolscine), and 1.14 (with 1 M rauwolscine). Means±s.e.mean from 4-11 slices. Significant differences from respective control: **P<0.01. Hippocampal slices were stimulated twice (SI, S2). Clonidine was added from 16 min before S2 onwards, 5-CT or 2-CH3-5-HT was present throughout superfusion. S2/S1 ratios obtained in the presence of clonidine were expressed as a percentage of the mean ratio of respective controls. S2/S1 control ratios were 1.12 (drug-free), 1.19 (with 5-CT), and 1.12 (with 2-CH3-5-HT). Means±s.e.mean from n slices. *P<0.05, **P<0.01 compared with the clonidine group in the absence of 5-CT or 2-CH3-5-HT, respectively. POP stimulation (Figure 4) . Yohimbine slightly affected Ca2+-independent tritium outflow under resting conditions, as previously observed (Allgaier et al., 1992 [3H]-NA release evoked from human neocortex slices with 360 pulses/3 Hz was independent of the age of the patients ( Figure  5 ). In addition, it was not influenced by the sex of the patients: the mean SI value from male patients was 6.13 ± 0.14 (n = 178), and that from female patients was 6.00 i 0.28 (n = 72).
Discussion
In the present study we investigated whether presynaptic 5 Feuerstein et al., 1992a) . rabbit hippocampus and human neocortex. In a previous study, performed on rabbit hippocampus ) 5-HT, as well as 5-CT, a nanomolar affinity 5-HT1 receptor agonist without significant affinity for 5-HT3 receptors (Pedigo et al., 1981; Heuring & Peroutka, 1987) , and 2-CH3-5-HT, a micromolar 5-HT3 receptor agonist having low affinity for either 5-HT, or 5-HT2 receptors (Richardson & Engel, 1986) , enhanced the electrically evoked release of [3H]-NA at Mmolar concentrations. The facilitatory effects of these compounds persisted in the presence of the non-selective aadrenoceptor antagonist, phentolamine. In the study of electrical stimulation was carried out with 360 pulses/3 Hz, a condition under which autoinhibition by released NA develops very rapidly (Valenta et al., 1988) . Using the same experimental paradigm we could confirm the capacity of 5-HT, 5-CT, and 2-CH3-5-HT to enhance electrically evoked noradrenaline release in rabbit hippocampus. However, facilitation of transmitter release was not blocked by the 5-HT3 receptor antagonist, tropisetron but was prevented by the a2-adrenoceptor antagonist, rauwolscine. Previous studies have shown that tropisetron and MDL 72222, another 5-HT3 receptor antagonist, inhibited the facilitatory effects of 5-HT agonists in rabbit hippocampus only at concentrations much higher than those required to block 5-HT3 receptors of the periphery . Rauwolscine by itself increased stimulus-evoked transmitter release approximately 6 fold, whereas phentolamine, a partial agonist at the a2-adrenoceptor (Heepe & Starke, 1985) caused only a 1.5 fold increase . Considering the prominent enhancement of release caused by rauwolscine it is noteworthy that evoked release in the presence of the a2-antagonist does not reflect maximum release under these conditions. Compounds such as the potassium channel inhibitor, tetraethylammonium chloride or the protein kinase C activator, 413-phorbol 12,13-dibutyrate, also enhanced transmitter release in the presence of a2-adrenoceptor antagonists (Heepe & Starke, 1985; Allgaier et al., 1987) .
The present results suggest that 5-HT, 5-CT, and 2-CH3-5-HT increased NA release by impairing autoinhibition. This hypothesis is supported by data from experiments in which autoinhibition was avoided by stimulating the tissue with 4 pulses/100 Hz (POP stimulation): (i) 5-HT and 5-CT were ineffective, whereas 2-CH3-5-HT decreased [3H]-NA release; (ii) the inhibition caused by 2-CH3-5-HT was not antagonized by tropisetron but by rauwolscine and the a2-adrenoceptor agonist, clonidine; (iii) the inhibition caused by clonidine was diminished by 5-CT or 2-CH3-5-HT. Since rauwolscine has been shown to be an agonist at the presynaptic 5-HTID autoreceptor in rabbit hippocampus (Feuerstein et al., 1985) and caudate nucleus (Feuerstein et al., 1992b) it has to be considered that it counteracted the enhancement of NA release via activation of inhibitory 5-HTID receptors. However, the typical 5-HT, receptor agonists, 5-HT and 5-CT, had no effect on NA release in the absence of autoinhibition so that the existence of in- (Allgaier et al., 1991b) . Since the effect of 3 nM clonidine was far from being maximal, inhibition caused by 2-CH3-5-HT should have been additive to that of the a2-agonist, if mediated by a receptor other than the a2-adrenoceptor.
Taken together, in rabbit hippocampus, 5-HT, 5-CT, and 2-CH3-5-HT modulated evoked NA release by acting on presynatic a2-adrenoceptors as partial agonist (2CH3-5-HT) or antagonist (5-HT, 5-CT). Furthermore the existence of autoinhibition dictates whether these drugs cause facilitation of release (autoinhibition present), inhibition or had no effect (no autoinhibition).
In human neocortex, [3H]-NA release induced with 360 pulses/3 Hz did not change with the age of the patients. This observation is in contrast to acetylcholine release which decreases with age (Feuerstein et al., 1992a (Feuerstein et al., 1990 ) was comparable to that measured for rabbit hippocampal slices. However, when autoinhibition was avoided by eliciting transmitter release with a modified POP stimulation, both 5-CT and 2-CH3-5-HT remained ineffective. The modified POP stimulation consisted of two bursts of 4 pulses at 100 Hz, 3.5 min apart and was used to obtain a sufficiently high [3H]-NA release from human neocortex slices. It has previously been applied also to rabbit brain tissue (Allgaier et al., 1992) . The data obtained with human neocortex tissue are in agreement with the antagonistic properties of 5-CT on presynaptic a2-adrenoceptors in the rabbit hippocampus. They reveal, in addition, species differences between human neocortex and rabbit hippocampus for which distinct a2-adrenoceptor subtypes might exist, since 2-CH3-5-HT inhibited NA release only in the rabbit in the absence of autoinhibition. For rabbit brain it was demonstrated that the a2-adrenoceptor regulating NA release belongs to the a2A subtype (Trendelenburg et al., 1993b) , whereas for human kidney tissue it was classified as a2C subtype (Trendelenburg et al., 1993a) .
In the literature, there are a number of reports demonstrating an affinity of 5-HT-receptor ligands for adrenoceptors and, conversely, of adrenoceptor ligands for 5-HT receptors. For example, the 5-HT2 antagonist, ketanserin, binds to aladrenoceptor in human, rat and pig brain (Hoyer et al., 1987), 5-methyl-urapidil shows equal affinity for O(1A-and 5-HTlAreceptors in rat cortex membranes (Grofi et al., 1987) , and the 5-HTI-receptor agonist, RU 24969, is a weak antagonist for presynaptic a2-adrenoceptors in rat cortex (Schlicker et al., 1988) .
The present data provide no evidence for the existence of presynaptic 5-HT receptors modulating NA release in rabbit hippocampus and human neocortex. The effects of 5-HT, 2-CH3-5-HT and 5-CT were most probably due to an interaction with presynaptic a2-autoreceptors. While this manuscript was in preparation Mongeau et al. (1994) reported that 2-CH3-5-HT enhanced NA release from slices of rat hippocampus via 5-HT3 receptors. However, Schlicker et al. (1994) demonstrated that facilitation of NA release from mouse cerebral cortex caused by the 5-HT3 receptor agonist 1-(m-chlorophenyl)-biguanide was due to a2-adrenoceptor blockade. In radioligand binding studies they determined the affinities of 2-CH3-5-HT and 5-CT for a2-adrenoceptors which correspond to the concentrations affecting NA release in the present study.
The present paper describes a facilitatory influence of 5-HT on NA release in human neocortex. In addition, there is another presynaptic interaction between the noradrenergic and the 5-hydroxytryptaminergic system in cortical tissue of animals (e.g. Feuerstein et al., 1985) and man (Feurerstein et al., 1993) , as endogenous NA inhibits 5-HT release via a2-heteroreceptors. This regulatory circuit between both neurotransmitter systems may have clinical implications since several CNS disorders may be based on interrelated disturbances of both, the noradrenergic and the 5-hydroxytryptaminergic neurotransmission, e.g. cyclothymia, pain syndromes and anxiety disorders.
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